Sanofi to transfer infectious disease research to Evotec

Evotec AG is to gain rights to a group of infectious disease assets from Sanofi SA in a transaction that will see the German company become a research hub for the development of medicines for diseases caused by bacteria, viruses, fungi and parasites.

Full text available to subscribers only. Click here for information on subscribing to MedNous.